Objectives: There is significant room for improvement in the development of tissue-engineered blood vessels (TEBVs) for vascular reconstruction. Most commonly, TEBVs are seeded with endothelial cells (ECs) only. This provides an antithrombogenic surface but suboptimal physiologic characteristics compared with native arteries, due to lack of smooth muscle cells (SMCs) in the vessel media. Although SMCs are critical in vessel architecture and function throughout the vascular tree, few studies have incorporated SMCs in TEBVs implanted in vivo. As such, the goal of the present study was to evaluate the effect of SMC coseeding with ECs on TEBV maturation, structure, and function after prolonged in vivo maturation. Methods: Dual-seeded TEBVs (dsTEBVs) were created by coseeding autologous ECs derived from circulating progenitor cells and SMCs from artery explants onto the lumen and outer surface of extracellular matrix scaffolds, respectively. Control vessels were seeded with ECs alone (ecTEBV). All vessels were preconditioned to pulsatile flow for 10 to 14 days in a bioreactor, implanted as arterial interposition grafts in sheep, and allowed to heal and adapt in vivo for 4 months before ex vivo physiologic testing and histologic analysis. Results: All implants were patent at 4 months. There were no structural failures, aneurysms, or infectious complications. The dsTEBVs exhibited a greater degree of wall maturation, characterized by higher medial cellularity (P ‫؍‬ .01) and greater percentage of ␣-actin (P ‫؍‬ .005) and SMC-specific muscle myosin heavy chain (P ‫؍‬ .005) staining compared with ecTEBVs. Contractile responses to phenylephrine and serotonin were significantly greater in isolated rings of dsTEBVs than those observed in ecTEBVs (P ‫؍‬ .01). Clinical Relevance: Bioengineering of functional blood vessels using autologous cells has been proposed as an alternative to prosthetic grafts for patients who lack suitable vein. Previous studies have focused on attaching endothelial cells to the luminal wall of prosthetic or tissue-engineered vessels. However, vascular smooth muscle cells (SMCs), which comprise the bulk of the artery wall, are essential in regulating artery wall geometry, tone, and integrity in response to a variety of hemodynamic and biochemical stimuli. Therefore, the addition of an SMC layer to an engineered blood vessel would enhance its function. This study evaluated the effect of incorporating vascular SMCs and endothelium into an engineered blood vessel that was implanted for 4 months in vivo. All vessels remained patent and maintained stable wall geometry without significant stenosis, dilation, or rupture. Dual-seeded vessels demonstrated enhanced structure and function with greater numbers of cells expressing SMC markers in the medial layer and significantly improved vasomotor responses than did vessels seeded with endothelium alone. This strategy may soon evolve into a clinically useful alternative for patients lacking vein for vascular reconstructions.
In situations where autologous vein is not available or is inadequate for clinical use as a vascular graft, the primary alternatives are prosthetic grafts such as Dacron and polytetrafluoroethylene. Although prosthetic grafts function well as conduits for reconstruction of large-diameter vessels, 1 they are susceptible to stenosis, thrombosis, and occlusion, particularly in diameters Ͻ6 mm or when connected to very small-caliber vessels such as coronary and tibial arteries. All prosthetic grafts also carry the risk of infection, with the need for subsequent graft excision. 2, 3 To address these shortcomings, autologous vascular grafts bioengineered using a patient's cells have been proposed as an alternative to current prosthetic materials when suitable vein is not available. [4] [5] [6] [7] [8] [9] The concept of engineering tissue using selective cell transplantation has been applied clinically for a variety of disorders, including the use of engineered skin, tracheal constructs, urinary bladder, and grafts for dialysis access. [10] [11] [12] [13] We have previously shown that tissue-engineered blood vessels (TEBVs) constructed with endothelial progenitor cell-derived endothelial cells (ECs) seeded onto decellularized arterial scaffolds can be used for carotid artery reconstruction in an ovine model. 14 In that study, TEBVs remained patent for Ͼ4 months and demonstrated cellular in-growth into the scaffold wall. Although the presence of a confluent EC monolayer on the luminal surface prolonged patency compared with unseeded control grafts, the contractile response of these grafts in vitro was still significantly less than the native artery, presumably due to a deficit of functional smooth muscle cells (SMCs) in the media. 14 In fact, SMCs comprise the bulk of the artery wall, where they are important in the maintenance of vessel architecture and mechanical properties as well as in modulating vascular tone in response to a variety of mechanical and biochemical stimuli. [15] [16] [17] Therefore, incorporating a SMC layer into a TEBV should enhance the function of the reconstructed artery. In this regard, we have recently developed methods to enhance SMC seeding of arterial scaffolds coseeded with ECs and demonstrated that bioreactor preconditioning accelerated the formation of the muscular layer on decellularized scaffolds, and furthermore, that this muscular layer was capable of mobilizing calcium in response to cellular depolarization. 18 Others have also documented contractile responses after SMC seeding of TEBVs in vitro, 9, 14, 18, 19 but we are aware of only one report demonstrating contractile responses after implantation and maturation in vivo, and in that report there was no detectable impact of 1 month of implantation in vivo on the observed contractile responses in vitro. 19 The goal of the present study was to evaluate the effect of coseeding of SMCs with ECs on TEBV structure and function after implantation in vivo. We hypothesized that not only would the addition of SMCs to the TEBV confer a more native artery-like phenotype but perhaps the presence of SMCs would also accelerate maturation, including gain of vasomotor function of the implanted TEBV. Consistent with this supposition, coseeding SMCs enhanced repopulation of the media by cells expressing SMC markers and resulted in significantly increased contractile responses compared with vessels seeded only with ECs at 4 months after arterial reconstruction in an ovine arterial interposition model.
MATERIALS AND METHODS
All animal procedures in this study were approved by the Wake Forest University Animal Care and Use Committee in compliance with accepted standards.
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Isolation and characterization of autologous SMCs and ECs. Female Dorper Cross sheep (aged 4 to 12 months) were purchased from RSI Farms (Mocksville, NC) and fed a standard diet (Rumilab, PMI, St. Louis, Mo). Endothelial progenitor cells were isolated from blood of anesthetized sheep using an affinity-based pheresis system to capture CD133ϩ cells, as previously described. 21 Briefly, 1800 mL of blood was cycled through an extracorporeal circuit containing a CD133-affinity column, between the femoral artery and vein. Bound CD133ϩ endothelial progenitor cells were eluted from the column with trypsin and cultured on fibronectin-coated plates in endothelial growth media (EGM-2, Cambrex, East Rutherford, NJ), as described. 21, 22 Media was changed at 5 and 8 days. After 10 days, colonies emerged that were expanded and characterized for typical growth and morphology. Expression of EC-specific markers (von Willebrand factor, vascular endothelial growth factor 2, endothelial nitric oxide synthase, and Ulex-Lectin) in cells derived with this system have recently been extensively characterized. 21 Autologous SMCs were cultured from a 3-cm section of femoral artery that was excised during the endothelial progenitor cell isolation procedure for each animal in the study. These artery segments were stripped of adventitia and opened longitudinally to denude the endothelium by gentle scraping. Pieces were cut to about 1 mm 2 , and attached to culture dishes, and then incubated in Dulbecco Modified Eagle's Medium with low glucose, L-glutamine, and 10% fetal bovine serum (Cambrex, East Rutherford, NJ), as previously described. 18 Migrated SMCs were passaged and expanded for graft seeding with ECs from the same animal.
Scaffold preparation. Decellularized porcine arterial segments were prepared as previously described. 14, 18 Briefly, common carotid arterial segments with an internal diameter of 4 to 5 mm were harvested fresh, cut to length, and washed in deionized water for 48 hours. Vessel segments were then incubated in 0.05% trypsin-ethylenediaminetetraacetic acid (Gibco, Invitrogen, Carlsbad, Calif) for 1 hour, followed by incubation in decellularization solution (490 mL distilled water, 10 mL Triton-100X, 3.4 mL ammonium hydroxide) for 3 days in a rotating shaker at 4°C. Decellularized extracellular matrix scaffolds were washed in deionized water for an additional 48 hours, frozen for 24 hours at Ϫ80°C, lyophilized, and sterilized with ethylene oxide. Immediately before seeding, scaffolds were rehydrated overnight in sterile phosphate-buffered saline (PBS) then rinsed with PBS before seeding.
Scaffold seeding and preconditioning. To construct the TEBVs, ECs and SMCs were trypsinized and resuspended in media at a density of 2 ϫ 10 6 and 5 ϫ 10 5 cells/mL, respectively. Scaffolds were mounted into a closed bioreactor with the lumen gently perfused with an EC suspension. For dual-seeded TEBVs (dsTEBVs), the SMC suspension was introduced into an outer chamber surrounding the scaffold. Scaffolds were rotated at 10 rpm for 2 hours at 37°C without fluid flow in the lumen. Flow was then initiated using a computer-operated gear pump (Ismatec, Glattbrugg, Switzerland) controlled by a custom LabVIEW program (National Instruments Corp, Austin, Tex) to flow EGM-2 through the lumen. Bioreactor preconditioning consisted of graded increases in lumen flow rate and shear stress, with a transition from steady to pulsatile flow 5 days after seeding, simulating arterial hemodynamic conditions (shear stress was 9.9 dynes/cm 2 during diastole and 13.2 dynes/cm 2 during systole), as previously described. 18, 22 This resulted in a biphasic pulse pressure wave without reversal of flow in diastole. 18 Pulsatile flow (60 cycles/min) was continued to at least day 10 with graft implantation from days 10 to 14.
TEBV implantation. Each animal (n ϭ 5 per group) received a TEBV produced from its own cells. Animals were given clopidogrel bisulfate (75 mg) and aspirin (325 mg) orally 1 day before and daily for 7 days after surgery. Two animals in each group had undergone prior carotid artery procedures, so the TEBVs were implanted as femoral interposition grafts, whereas all other grafts were implanted as common carotid artery interposition grafts. Consistent with the relative similarities in the hemodynamic environment and structural characteristics of these two vessels, our preliminary observations did not reveal any obvious differences in the salient characteristics of the retrieved vessels evaluated. As such, we considered all grafts to represent a homogeneous population for purposes of statistical analysis for these initial studies.
Under general anesthesia, the target artery was exposed and controlled with vessel loops. Heparin was administered (100 U/kg, i.v.) and vessel loops were secured before a 5-cm length of artery was excised. The TEBV (6-cm long) was sutured end-to-end as interposition graft using running 6-0 polypropylene suture. Incisions were closed in two layers with absorbable suture. After the animals were recovered, they were returned to standard housing until the TEBVs were explanted 4 months later.
TEBV patency and geometry. After implantation, the bioengineered vessels were examined by palpation three times per week and monthly by duplex ultrasound imaging (Sequoia, Acuson Inc, Mountain View, Calif). Midgraft cross-sectional diameter and Doppler velocity waveforms were assessed in the native artery, across anastomoses, and in the mid-TEBV to qualitatively exclude stenoses. Representative animals also underwent digital subtraction angiography imaging at the time of necropsy.
Histology. The TEBVs were explanted under general anesthesia. Animals received heparin, the TEBV was removed and rinsed with PBS, and rings were then cut from the midgraft for physiologic testing. The remaining midgraft was fixed by formalin perfusion and three 5-mm rings were cut from each and embedded in paraffin for histologic analysis. Adjacent sections were cut from each ring and stained with hematoxylin and eosin (H&E) and Movat stains or were processed for immunohistochemistry. Antibodies specific for ␣-actin (1:500; Millipore, Billerica, Mass) and a myosin heavy chain (MHC) isoform, previously reported 23 to distinguish arterial SMCs from fibroblasts/myofibroblasts (1:500; clone BT-562, Biomedical Technologies, Stoughton, Mass, after antigen retrieval in heated citrate buffer, pH 6.0) were applied to sections as previously described. 23, 24 Primary antibodies were localized with biotinylated secondary antibody (1:400; VectorLabs, Marion, Iowa) after blocking in 5% horse serum (Gibco), followed by the ABC reaction (Vectastain Elite, VectorLabs) with diaminobenzidine as the chromogen (Sigma, St. Louis, Mo).
Sections were viewed with standard light microscopy, and medial cell density was determined by averaging nuclei/high power field (original magnification ϫ400) in 4 quadrants of each cross-section using a predetermined algorithm of centering the field equidistant between internal and external elastic laminas at 12, 3, 6, and 9 o'clock. Similarly, adjacent cross-sections from each ring were stained for ␣-actin and MHC, and the number of positively stained cells was quantified using the same algorithm used for total cell numbers.
Physiologic testing. Rings from the center of each TEBV were cut into three equal 2.5-mm segments, and rings of similar dimensions were cut from the contralateral common carotid or femoral artery as an intra-animal reference vessel. Each ring was placed in an organ bath (Radnoti, Monrovia, Calif) containing standard Krebs-Ringers solution continuously bubbled with 95% O 2 and 5% CO 2 at 37°C to obtain a pH of 7.4, and mounted on stainless steel hooks connected to a force transducer (ADI Instruments, Colorado Springs, Colo), as previously described. 25 Tissues were equilibrated at a basal tension of 1.0 g (L max ) and constant length for 30 minutes. Maximal steady-state contractions were then elicited by adding KCl (60mM; general depolarization of the cell membrane), phenylephrine (10 M; ␣ 1 -adrenergic agonist), and 5-hydroxytryptamine (5-HT; 10 M; 5-HT 2 agonist) to each ring. Isometric contractions were recorded using a PowerLab data acquisition unit and analyzed by Chart5 software (AD Instruments, Colorado Springs, Colo).
Statistical analysis. Group-wise comparisons between the dsTEBVs and ecTEBVs were made for cell density, SMC markers, and physiologic parameters using an unpaired t test with significance set at ␣ ϭ .05. All statistical analysis was performed using GraphPad Prism 4.0 software (GraphPad, La Jolla, Calif).
RESULTS
Decellularized scaffolds averaged a 5 mm inner diameter and 6 cm in length at implantation after bioreactor preconditioning (Fig 1, A) . Preimplantation histology demonstrated multiple layers of SMCs on the outer wall, with minimal penetration of the scaffold wall (Fig 1, B) . A luminal endothelial monolayer was also present, with a paucity of underlying SMCs (Fig 1, A, C) . Grafts demonstrated easy handling, solid suture retention, rapid hemostasis at the suture line, and no transgraft bleeding, despite the use of antiplatelet agents and heparin (Fig 1, D) . All grafts (n ϭ 5 per group) were patent at 4 months after implantation when removed for ex vivo analysis (Fig 1, E) . No grafts demonstrated significant stenosis, aneurysm/ pseudoaneurysm, or thrombosis by duplex imaging (not shown), angiography (Fig 1, E) , or upon examination ex vivo. All grafts were well incorporated at the time of explant, without purulence or acute inflammation. One graft from the ecTEBV group was not suitable for physiologic studies due to extensive vessel wall calcification.
Histologic analysis. Three main findings document that dsTEBVs exhibited a greater degree of tissue maturation than ecTEBVs. First, as illustrated in Fig 2, Second, the percentage of cells in the TEBV wall that stained positive for ␣-actin and smooth muscle MHC was much higher in the dsTEBV group than in the ecTEBV group (Fig 3) . A summary of these data and the corresponding statistical conclusions are graphically depicted in Fig 4. Third, from a qualitative perspective, it was interesting to note that compared with the dsTEBVs, the ecTEBVs demonstrated cells primarily in the outer portions of the rings, suggesting that the cells infiltrating the scaffold wall most likely migrated from the extraluminal side inward.
Finally, a Movat stain is included that shows elastic scaffold components, illustrating the internal and external elastic lamellae of the scaffolds and the paucity of neointima in these midgraft segments (Fig 2) .
Physiologic studies in vitro evaluating contractile function. Pharmacologic studies were conducted to determine the maximal amplitude of the steady-state contractile responses observed on retrieved dsTEBVs and ecTEBVs to the physiologically relevant spasmogens, phenylephrine and 5-HT, as well as in response to depolarization with KCl. Representative examples of the responses to phenylephrine and 5-HT are shown in Fig 5, with mean values for all experiments shown in Fig 6. As illustrated, the maximal amplitude of the phenylephrine-and 5-HTinduced contractile responses in the dsTEBVs were significantly larger than those observed for ecTEBVs. Specifically, the mean values for the maximal phenylephrine-induced contractile responses were 0.27 Ϯ 0.03 g (n ϭ 17) for dsTEBVs and 0.16 Ϯ 0.02 g (n ϭ 13) for ecTEBVs (P ϭ .01). The corresponding values for 5-HT were 0.54 Ϯ 0.08 g (n ϭ 17) for dsTEBVs and 0.25 Ϯ 0.02 g (n ϭ 13) for ecTEBVs (P ϭ .01). However, statistically significant differences in contractile response were not seen with stimulation by KCl, where the corresponding values for dsTEBVs were 0.15 Ϯ 0.02 g (n ϭ 13) and 0.15 Ϯ 0.01 g (n ϭ 13; Fig 6) .
The values for contraction reported for the ecTEBVs are similar to a previous report.
14 However, despite the enhanced contractility of the dsTEBV grafts over the ecTEBV grafts, the maximal contractile response seen with phenylephrine and 5-HT was still only about 15% to 20% of that observed for the corresponding responses of the native artery from these same animals, which were 1.4 Ϯ 0.2 g (n ϭ 24) for phenylephrine and 4.1 Ϯ 0.7 g (n ϭ 24) for 5-HT. Similarly, the KCl-induced maximal contractile response of the normal contralateral native carotid artery was 1.6 Ϯ 0.4 g (n ϭ 24).
DISCUSSION
A truly functional engineered blood vessel has been called "The Holy Grail of Peripheral Vascular Surgery." 26 Patients without suitable vein have few options for medium-to small-diameter arterial bypass procedures. Prosthetic grafts perform poorly in these situations, prompting the search for alternatives. 27 Recent advances in tissue engineering have culminated in clinical pilot studies of blood vessels seeded with autologous cells for arterial reconstruction and for AV grafts. 4, 8, 13, 14, 19, [28] [29] [30] Although other groups have constructed TEBVs with various supporting cell types, including SMC, cells like SMCs, adiposederived stem cells, and fibroblasts, there is very little evi- dence that in vivo maturation results in a functional medial SMC layer. 8, 13, 14, 19, [29] [30] [31] [32] In the present study, we demonstrated that SMC seeding and preconditioning resulted in a TEBV with enhanced contractile responses to relevant agonists after in vivo maturation. Contractile function in dsTEBVs was associated with increased medial cell density and with an increase in the fraction of cells expressing SMC-specific markers compared with grafts seeded only with ECs.
From a clinical perspective, limited graft patency is a major problem. Several factors contribute to graft occlusion, including acute thrombosis and anastomotic intimal hyperplasia. [33] [34] [35] The role of ECs in preventing thrombosis has been well documented. 33, 34, 36, 37 A functional endothelium may also limit SMC proliferation and intimal hyperplasia as well as promote vasodilation. Also important to clinical application is having conduit available in a wide range of sizes on short notice. In the present study we attempted to construct vessels in a clinically relevant time frame of about 6 weeks to implantation. The relatively brief period of culture after seeding of the scaffold (10 to 14 days) was adequate to achieve a confluent endothelium 14 but limited the mass of SMCs present at implantation. Improvements in scaffold design and cell isolation and seeding could further shorten time to implantation, but engineering conduits for emergency applications will require different approaches than those used here.
Creating a truly functional vessel will also require complex integration of endothelium and an SMC layer responsive to biochemical and hemodynamic cues. Bioengineering blood vessels with SMCs presents a significant challenge in achieving relevant numbers of cells in a brief period of time. 13 Conversely, vessels implanted with too few SMCs may fail to repopulate adequately secondary to SMC senescence or attrition during graft wall healing and maturation. To facilitate SMC adaptation and potentially survival on implantation, we used a preconditioning protocol to mimic arterial pressure and strain. From our previous experiments, 18 we found that this allows SMCs to accumulate and lay down new extracellular matrix before implantation and likely prepares them for the stress-strain in vivo after implantation. Despite the relatively small number of SMCs present on grafts at implantation (Fig 1, A and B ) they were associated with extensive repopulation of the media compared with the limited cellularity of grafts seeded only with ECs (Figs 2-4) .
These data clearly indicate that the presence of the SMCs contributes to medial healing, but further studies using labeled SMCs that can be tracked over time would be required to confirm a direct contribution from seeded cells vs enhanced in-growth of new host-derived SMCs or their progenitors. Our observation of in-growth of host cells into the implanted graft is consistent with prior studies involving engineered vascular tissue. 8, 13, 14, 19, [29] [30] [31] [32] Some cells in the TEBV wall that exhibited morphologic features consistent with SMCs as well as ␣-actin staining, were also negative for the presence of the SMCspecific marker (MHC). These cells likely represent the presence of myofibroblasts. 19, 29 We documented a greater fraction of cells that expressed both ␣-actin and smooth muscle MHC in dsTEBVs, but less overlap was noted in the ecTEBV group. This observation leads us to believe that perhaps the host cellular infiltrate responsible for the physiologic response in ecTEBVs was partly compromised by the presence of myofibroblasts. Although some groups have preferentially used fibroblasts to construct TEBVs, 13 fibroblasts are not likely to produce the same degree of functionality obtained with SMCs or SMC progenitors, particularly for applications in medium and small arteries where vasomotor responses are more important than for large-conduit arteries. However, directly comparing contractile responses in vessels constructed with fibroblasts vs SMCs would be required to define the potential of each cell type to produce physiologic responses after maturation in vivo.
We have previously shown that SMC seeding of decellularized scaffolds can be enhanced by removing the adventitial layer before seeding the outer graft wall. 18 In initial in vitro experiments, we tried seeding SMCs inside the graft, as in previous studies, using porous polytetrafluoroethylene. 38 However, the SMCs did not migrate into the inner scaffold wall but instead formed a neointima. We were thus concerned about intimal thickening and stenosis if we implanted such grafts, so we altered seeding, placing SMCs on the outer graft and reported that removing the adventitia promoted cell accumulation and penetration of the outer wall without weakening the scaffold significantly. 18 Combining preconditioning to pressure and flow further enhanced development of a muscular coat compared with grafts seeded under static conditions. In those studies, the resulting vascular constructs demonstrated a physiologic response to depolarization with KCl (ie, intracellular calcium mobilization) in vitro. 18 However, no receptormediated calcium mobilization response was seen with the addition of phenylephrine or 5-HT. These previous observations create an interesting phenotypic difference relative to our current observations. The current study has demonstrated that not only do TEBVs develop contractile responses to these particular agonists when allowed to mature in vivo for 4 months (ie, using the body as the final bioreactor/incubator) but that SMC seeding is also associated with increased TEBV wall cellularity and increased contractile responses compared with grafts seeded only with ECs (Figs 5 and 6) .
Potential limitations. Despite 4 months of maturation in vivo, we observed that TEBVs produced only a fraction of the contractile response seen in native vessels (eg 15% to 20% of carotid artery). There may be several reasons for this. First, cells that exhibited an SMC phenotype from the histologic and morphologic perspective, may have an altered receptor density, distribution, and/or subtype and, thereby, incomplete/altered cell signaling and excitationcontraction coupling relative to native artery media. That is, perhaps not all of the cells in the vessel wall are capable of contributing to the agonist-induced contractile responses. In addition, using a single time point limited our understanding of whether wall function was improving, stable, or perhaps deteriorating over time. Additional studies will be necessary to focus on the timing of the functional changes that occur in the TEBV wall over time.
Another limitation of our study design is that cells were not labeled and monitored over time to ensure that ob- served differences between groups were from a direct effect of seeded cells or an indirect effect of having cells present at implantation but perhaps not direct repopulation of the TEBV wall by seeded cells. There are data in the literature to support a direct contribution from seeded SMCs in the ovine model, 30 whereas other investigators postulate an indirect benefit from preseeding scaffolds with cells that affects subsequent immune response. 31 Further experiments will be necessary to address the underlying mechanism.
Although our technique for EC isolation can be made minimally invasive for clinical applications, isolating SMCs from artery biopsy specimens is impractical for patients. Alternative strategies to obtain large numbers of SMC precursors in a shorter time frame will be necessary, ideally from circulating progenitors.
Finally, although we did not see any evidence for aneurysmal degeneration or stenoses, validating this approach in other preclinical models will be desirable before clinical trials.
CONCLUSIONS
In earlier studies, we demonstrated methods for the optimization of the in vitro preconditioning of tissue engineered vascular grafts that contain SMCs. The current study demonstrates that incorporating SMCs on the outside of a TEBV wall combined with preconditioning to arterial hemodynamics was associated with increased population of the TEBV wall by SMCs in a large-animal model of arterial reconstruction. Moreover, SMC seeding conferred a corresponding greater physiologic response to receptor-mediated agonists compared with TEBVs seeded with ECs only. Further studies are needed to define whether vessels allowed to mature for longer periods of time in vivo will become even more functionally and histologically similar to native blood vessels. 
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